Drugs / ECT204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04864054 | Mar 2022 → Dec 2027 expected | adult hepatocellular carcinoma | Eureka Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECT204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04864054 ↗ |
| Action | Deplete | “selectively recognize and eliminate GPC3-expressing HCC tumor cells.” NCT04864054 ↗ |
| Modality | Cell therapy | “ECT204 is an autologous T-cell therapy” NCT04864054 ↗ |
| Target | GPC3 | “GPC3-targeting surface components” NCT04864054 ↗ |